This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vasey, P. A. Articles by Kaye, S. B. Search for Related Content PubMed PubMed Citation Articles by Vasey, P. A. Articles by Kaye, S. B. Social Bookmarking                            What's this?

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer

From the Beatson Oncology Centre and Stobhill Hospital, Glasgow, Royal Marsden Hospital, Surrey, and Imperial College and Imperial Cancer Research Fund, London, United Kingdom; and Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, MA.

Address reprint requests to Paul Vasey, MD, Cancer Research Campaign Department of Medical Oncology, Cancer Research Campaign Beatson Laboratories, Garscube Estate, Switchback Rd, Glasgow G61 1BD, United Kingdom; email: pav1y{at}clinmed.gla.ac.uk

PURPOSE: Resistance to chemotherapy in ovarian cancer is frequently associated with mutations in the p53 gene. The adenovirus dl1520 (ONYX-015) with the E1B 55-kd gene deleted, allowing selective replication in and lysis of p53-deficient tumor cells, has shown preclinical efficacy against p53-deficient nude mouse-human ovarian carcinomatosis xenografts.

PATIENTS AND METHODS: We undertook a phase I trial of intraperitoneal dl1520 in patients with recurrent ovarian cancer. Sixteen women with recurrent/refractory ovarian cancer received 35 cycles (median, two cycles) of dl1520 delivered on days 1 through 5 in four dose cohorts: 1 x 10⁹ plaque forming units (pfu), 1 x 10¹⁰ pfu, 3 x 10¹⁰ pfu, and 1 x 10¹¹ pfu.

RESULTS: The most common significant toxicities related to virus administration were flu-like symptoms, emesis, and abdominal pain. One patient receiving 1 x 10¹⁰ pfu developed common toxicity criteria grade 3 abdominal pain and diarrhea, which was dose-limiting. The maximum-tolerated dose was not reached at 10¹¹ pfu, and at this dose level patients did not experience significant toxicity. There was no clear-cut evidence of clinical or radiologic response in any patient. Blood samples were taken for adenovirus DNA and neutralizing antibodies. Polymerase chain reaction data indicating presence of virus up to 10 days after the final (day 5) infusion of dl1520 are suggestive of continuing viral replication.

CONCLUSION: This article therefore describes the first clinical experience with the intraperitoneal delivery of any replication-competent/-selective virus in cancer patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				X. Huang, L. Zhuang, Y. Cao, Q. Gao, Z. Han, D. Tang, H. Xing, W. Wang, Y. Lu, G. Xu, et al. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration Mol. Cancer Ther., June 1, 2008; 7(6): 1624 - 1632. [Abstract] [Full Text] [PDF]

				J. Leyton, M. Lockley, J. L. Aerts, S. K. Baird, E. O. Aboagye, N. R. Lemoine, and I. A. McNeish Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging. Cancer Res., September 15, 2006; 66(18): 9178 - 9185. [Abstract] [Full Text] [PDF]

				R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]

				T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]

				K. Hasegawa, L. Pham, M. K. O'Connor, M. J. Federspiel, S. J. Russell, and K.-W. Peng Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res., March 15, 2006; 12(6): 1868 - 1875. [Abstract] [Full Text] [PDF]

				M. Lockley, M. Fernandez, Y. Wang, N. F. Li, S. Conroy, N. Lemoine, and I. McNeish Activity of the Adenoviral E1A Deletion Mutant dl922-947 in Ovarian Cancer: Comparison with E1A Wild-type Viruses, Bioluminescence Monitoring, and Intraperitoneal Delivery in Icodextrin Cancer Res., January 15, 2006; 66(2): 989 - 998. [Abstract] [Full Text] [PDF]

				J. Zhou, Q. Gao, G. Chen, X. Huang, Y. Lu, K. Li, D. Xie, L. Zhuang, J. Deng, and D. Ma Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability Clin. Cancer Res., December 1, 2005; 11(23): 8431 - 8440. [Abstract] [Full Text] [PDF]

				D. T. Rein, M. Breidenbach, T. O. Kirby, T. Han, G. P. Siegal, G. J. Bauerschmitz, M. Wang, D. M. Nettelbeck, Y. Tsuruta, M. Yamamoto, et al. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1327 - 1335. [Abstract] [Full Text] [PDF]

				V. V. Ternovoi, L. P. Le, N. Belousova, B. F. Smith, G. P. Siegal, and D. T. Curiel Productive Replication of Human Adenovirus Type 5 in Canine Cells J. Virol., January 15, 2005; 79(2): 1308 - 1311. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				N R Lemoine and I A McNeish Gene transfer: Bax to the future for cancer therapy Gut, April 1, 2004; 53(4): 478 - 479. [Full Text] [PDF]

				N. Senzer, S. Mani, A. Rosemurgy, J. Nemunaitis, C. Cunningham, C. Guha, N. Bayol, M. Gillen, K. Chu, C. Rasmussen, et al. TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors J. Clin. Oncol., February 15, 2004; 22(4): 592 - 601. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				I. Ganly and B. Singh Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus? J. Clin. Oncol., December 15, 2003; 21(24): 4476 - 4478. [Full Text] [PDF]

				J. S. Berek, B. C. Schultes, and C. F. Nicodemus Biologic and Immunologic Therapies for Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 168s - 174. [Abstract] [Full Text] [PDF]

				O. Hamid, M. L. Varterasian, S. Wadler, J. R. Hecht, A. Benson III, E. Galanis, M. Uprichard, C. Omer, P. Bycott, R. C. Hackman, et al. Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., April 15, 2003; 21(8): 1498 - 1504. [Abstract] [Full Text] [PDF]